Stock ANNX BTA ANNEXIN PHARMACEUTICALS AB (PUBL)
Add to a list
To use this feature you must be a member
Log inSign up

Financials Annexin Pharmaceuticals AB (publ) Nasdaq Stockholm

Equities

ANNX BTA

SE0013748894

Biotechnology & Medical Research

Delayed Nasdaq Stockholm
Other stock markets
 		5-day change 1st Jan Change
- SEK -.--% Intraday chart for Annexin Pharmaceuticals AB (publ) -3.17% -.--%
05-23 Annexin Pharmaceuticals AB Elects Mikael Lönn as New Ordinary Member of the Board of Directors CI
04-30 Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals CI

Valuation

Fiscal Period: December 2019 2022 2023 2024 2025
Capitalization 1 31.12 154.2 88.39 156.7 -
Enterprise Value (EV) 1 27.09 154.2 66.97 138.3 156.7
P/E ratio -1.1 x - - - -
Yield - - - - -
Capitalization / Revenue - - - - 3.96 x
EV / Revenue - - - - 3.96 x
EV / EBITDA -1.12 x -3.8 x - -2.65 x -9.44 x
EV / FCF -1,052,952 x - - - -
FCF Yield -0% - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 17,684 154,498 339,949 346,584 -
Reference price 2 1.760 0.9980 0.2600 0.4520 0.4520
Announcement Date 1/28/20 2/7/23 2/9/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2021 2022 2023 2024 2025
Net sales 1 - - - - - 39.6
EBITDA 1 -24.1 - -40.53 - -52.1 -16.6
EBIT 1 -28.33 - -40.72 -44.18 -52.1 -16.6
Operating Margin - - - - - -41.92%
Earnings before Tax (EBT) 1 -28.36 - -40.73 - -52.1 -16.6
Net income 1 -28.36 -52.14 -40.73 -44.05 -52.1 -16.6
Net margin - - - - - -41.92%
EPS -1.600 - - - - -
Free Cash Flow -25.72 - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 1/28/20 2/3/22 2/7/23 2/9/24 - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2021 2022 2023 2024 2025
Net Debt 1 - - - - - -
Net Cash position 1 4.04 - - 21.4 18.4 -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow -25.7 - - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 1/28/20 2/3/22 2/7/23 2/9/24 - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.15% 124B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.02% 112B
ARGENX SE Stock argenx SE
+4.45% 22.94B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.86% 17.02B
GENMAB A/S Stock Genmab A/S
-16.52% 16.88B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.94% 16.87B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.80% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.39% 11.61B
INSMED INCORPORATED Stock Insmed Incorporated
+106.26% 10.31B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ANNX Stock
  4. ANNX BTA Stock
  5. Financials Annexin Pharmaceuticals AB (publ)